Aquestive 制药

最新新闻

• 评级变动
  Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $11
  \u5e02\u573a\u8d44\u8baf · 2026/3/2
• Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
  TipRanks · 2026/6/26
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Aquestive Therapeutics (AQST) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
  TipRanks · 2026/2/2
• 评级变动
  A. G. P. Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $9
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• 评级变动
  A. G. P. Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Announces Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/3/9
• 评级变动
  Oppenheimer Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/6/25
• Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 评级变动
  Leerink Partners Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Announces Target Price $9
  \u5e02\u573a\u8d44\u8baf · 2026/3/6
• 评级变动
  Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Cuts Target Price to $8
  \u5e02\u573a\u8d44\u8baf · 2026/1/14
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT)
  TipRanks · 2026/5/15
• 评级变动
  A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9
  \u5e02\u573a\u8d44\u8baf · 2026/5/16
• 评级变动
  Piper Sandler Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/5/15
• 评级变动
  LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $9
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• Cantor Fitzgerald Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• 评级变动
  Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/1/9
• H.C. Wainwright Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Raises Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $8 to $12
  \u5e02\u573a\u8d44\u8baf · 2026/2/3

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。